Thank you Tiago. Um, next slide please. So before I turn to the label itself, let me start with the clinical evidence submitted in the NDA. This package rests on two pillars. First, three clinical studies, Triac Trial I, which established the core effect of EMCITATE in lowering T3 and improving the clinical markers of thyrotoxicosis. ReTRIACt, the randomized withdrawal study, delivered confirmatory placebo-controlled evidence that this T3-lowering effect is directly attributable to EMCITATE, and Triac Trial II, which added safety data at higher doses in the youngest patients, together with three independent sources of real-world evidence, the Erasmus Medical Center cohort study, followed patients for up to six years, confirming that the effect on T3 and clinical markers of thyrotoxicosis are durable over the long term. The EMC Survival study, which examined treated versus untreated patients in a cohort of more than 600 individuals, and the U.S. Expanded Access program showed that the real-world experience in the U.S. was consistent with everything we had seen in the clinical trials. From this clinical package, really two things stand out. First, the robustness of the data behind EMCITATE, which is unusually complete for an ultra-rare genetic disease. And second, the consistency of the results across different designs, different populations, and different settings.
And building on what you heard Tiago just described, the biological plausibility of the treatment effects seen in our clinical data has been key in the NDA package. Thyrotoxicosis is a well-characterized condition. It is linked to cardiovascular and metabolic harm, which is extensively documented, and correcting the thyroid hormone excess is known to reverse it. With EMCITATE lowering the elevated T3, we see the expected clinical benefits also in patients with MCT8 deficiency. So the clinical data in the NDA package do not stand alone. They sit on top of well-established biology. Every piece of data we have moved in the same direction, and that coherence is what underpins our confidence in the clinical package. Next slide please. So, turning to the label itself. Key here is the broad indication statement covering all patients with MCT8 deficiency, saying that EMCITATE is a thyroid hormone receptor agonist indicated for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with MCT8 deficiency. With this approval, EMCITATE becomes the first and only approved therapy for these patients in the United States. The remainder of this slide gives a brief overview of the highlights of the USPI. The class black box warning, how the medicine is dosed and individualized. The dosage forms, the warnings, and precautions. The contraindications. The most common adverse reactions and drug interactions. I won't go through each of these in detail here. The full approved prescribing information is the definitive source, and it is linked on this slide for anyone who would like to see the complete safety and usage information. Next slide please. Here we see how the clinical data package translates into section 14 of the USPI. In other words, which studies the FDA considered adequate and well-controlled to provide the primary support of effectiveness. Two studies are included. ReTRIACt is. ReTRIACt is the randomized withdrawal study. It gives us two findings. First, the rate of T3 change, where total T3 rose 1.5 times faster on placebo than on EMCITATE during the randomized treatment period, with a p-value of 0.034. Second, the need for rescue, where four out of eight patients on placebo met the rescue criterion of total T3 above the upper limit of normal versus one out of seven on EMCITATE. I would note the asterisks here that that single case was a participant who discontinued prematurely for reasons not related to the drug, and was counted as having met the criteria. What is also worth emphasizing is the consistency. Every patient randomized to placebo had a larger increase in total T3 than any participant who continued on EMCITATE. EMCITATE. Triac Trial I. Triac Trial I is study two. A 12-month open-label study where we saw a reduction in mean total T3 from 323 to 118 nanograms per deciliter over a year, a change of -205, with a p-value below 0.0001. Alongside that, key clinical markers of thyrotoxicosis improved: systolic blood pressure down, heart rate down, and body weight-for-age z-score up. All three secondary endpoints moved in the direction of reduced peripheral thyrotoxicosis, which is positive to have acknowledged in labeling. Given the importance of improvement of thyrotoxicosis in this patient population, as previously covered by Christian Sonesson. The EMCITATE survival study was not included in labeling. It's important to remember that this study is a retrospective, real-world cohort study, and the scientific and regulatory perspective on rigor is slightly different. And ultimately, the FDA considered that, given the limitations of the retrospective, real-world design, the study did not meet the regulatory requirements for an adequate and well-controlled study. But certainly, from a scientific perspective, we are confident that the EMC-survival study is unprecedented, and the data have been shown to be robust across a multitude of different sensitivity analyses. Instead, in the short term, we look forward to seeing the EMCITATE survival study published so that the scientific and clinical community can be informed about the study.
With that, I hand over to Anny Bedard, our President of North America, to cover the U.S. launch readiness.